Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 6, Pages 1291-1299
Publisher
Informa UK Limited
Online
2016-01-14
DOI
10.3109/10428194.2015.1128540
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
- (2015) C. Y. Cheah et al. BLOOD
- How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
- (2014) A. P. Kater et al. BLOOD
- Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
- (2014) J.-F. Fecteau et al. BLOOD
- Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium
- (2014) Danelle F. James et al. JOURNAL OF CLINICAL ONCOLOGY
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
- (2011) X. C. Badoux et al. BLOOD
- Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
- (2011) Emilio Iannitto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
- (2011) Clemens-Martin Wendtner et al. LEUKEMIA & LYMPHOMA
- Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
- (2010) Asher Chanan-Khan et al. CANCER
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options
- (2010) Apostolia-Maria Tsimberidou et al. LEUKEMIA & LYMPHOMA
- Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
- (2010) Taimur Sher et al. LEUKEMIA & LYMPHOMA
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
- (2009) R. Lapalombella et al. BLOOD
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
- (2008) Leslie A. Andritsos et al. JOURNAL OF CLINICAL ONCOLOGY
- Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- (2008) Apostolia-Maria Tsimberidou et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started